3 New Strong Buy Ratings from Top-Rated Analysts: 03/18/2025
What the heck do you buy in a market like this? Wall Street’s top analysts have opinions. Here’s a peek at the latest from our Strong Buy Stocks from Top Wall Street Analysts screener:
- JD.com (NASDAQ: JD) is currently surging. Keep reading to find out why (and why it could continue)
- Ever heard of Vistra Corp (NYSE: VST)? It was only one of the top S&P performers of 2024…
- Find out why Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) could go up nearly $100 in the coming year, according to experts
(P.S. You can get even more picks like this daily — Try WallStreetZen Premium today)
1. JD.com (NASDAQ: JD)
One of the titans of e-commerce in China, JD.com is the country’s largest retailer by revenue. Despite a 55.89% surge over the past year, the stock potentially remains undervalued — and analysts estimate that plenty of further growth is to come in 2025. With a recent earnings beat and a substantial share buyback program at play, JD stock is worth a closer look — particularly for investors eager to diversify.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $41.24 — get current quote >
Max 1-year forecast: $58.00
Why we’re watching:
- A consensus Strong Buy, JD.com currently has 5 Strong Buy ratings and 2 Buy ratings — with not a single Hold, Sell, or Strong Sell rating. See the ratings
- Barclays’ Gregory Zhao (a top 21% rated analyst) maintained a Strong Buy rating and increased his price target for JD.com stock from $50 to $55 ahead of the company’s Q4 and FY 2024 earnings call.
- In a note shared with investors, Zhao attributed the hike to China’s $41 billion consumption stimulus.
- Following the quarterly report, which saw both EPS and revenues beat estimates, Fawne Jiang of Benchmark (a top 6% rated analyst) also doubled down on an earlier Strong Buy rating, and upped their price target from $47 to a Street-high $58, a figure that implies a 42.72% upside.
- The analyst pointed out that management offered "upbeat" FY 2025 guidance, expecting revenue and net profit to expand by high single digits instead of the mid-single digits predicted by the Street.
- With an overall Zen Rating of A, JD stock belongs to a class of equities that have delivered an average annual return of 32.52% since the turn of the millennium.
- At present, JD.com stock ranks in the top 4% and top 9% in terms of its Growth Component Grade rating and Value Component Grade rating, respectively. (See all 7 Zen Component Grades here >)
2. Vistra Corp (NYSE: VST)
Vistra Corp was one of the best performing companies in the entire S&P 500 in 2024. Although you might not know it, that’s a bit odd — as it is a utilities business. Despite belonging to what is traditionally considered a defensive sector, robust demand for power-hungry data centers drove quite a lot of growth last year — and there’s no reason to believe that demand will let up any time soon.
Zen Rating: B (Buy) — see full analysis >
Recent Price: $118.00 — get current quote >
Max 1-year forecast: $202.00
Why we’re watching:
- Those 2024 returns were beyond impressive, at 257.9%.
- Despite prices skyrocketing, analysts are confident that there’s more room to grow for VST stock. At present, 8 researchers track the stock and issue ratings for it — 5 of which have deemed it a Strong Buy, while 3 analysts gave the stock a Buy rating. There are currently no Hold, Sell, or Strong Sell ratings for Vistra Corp stock. See the ratings
- Bank of America’s Julien Dumoulin-Smith (a top 7% rated analyst) upgraded VST shares from a Buy to a Strong Buy on March 4. In addition, the BofA analyst cut the 12-month price forecast for the stock from $164 to $152.
- Dumoulin-Smith said that although the stock price has declined 27% over the past few weeks because of a lack of data center news, BoA believes Vistra's base business of baseload generation and competitive retail are well-positioned to benefit from tightening markets, increasing demand and retail growth, regardless of data center deals.
- With an overall Zen Rating of B, Vistra Corp stock ranks in the top 20% of equities tracked by our quant rating system.
- Two of the energy company’s strongest suits are Growth and Financials — categories in which it is 80th and 89th percentile, respectively (See all 7 Zen Component Grades here >)
3. Jazz Pharmaceuticals PLC (NASDAQ: JAZZ)
Jazz Pharmaceuticals has established itself as a leader in sleep disorder therapeutics. This, along with a recent strategic acquisition, has piqued the interest of Wall Street analysts, who predict a significant upside on average. Best of all — Jazz is trading at quite an attractive valuation, and offers an appealing risk/reward ratio, particularly compared to other biotech stocks.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $136.05 — get current quote >
Max 1-year forecast: $230.00
Why we’re watching:
- In total, 12 analysts track JAZZ stock and issue ratings for it — 7 have deemed it a Strong Buy, 4 have given the stock a Buy rating, and a single analyst currently issues a Hold rating. See the ratings
- Truist Securities researcher Gregory Fraser (a top 18% rated analyst) reiterated an earlier Strong Buy rating on March 6, and increased his price target for Jazz Pharmaceuticals stock from $220 to a Street-high $230.
- Fraser pointed to the company’s $935 million acquisition of Chimerix (NASDAQ: CMRX), as the key driver behind the price target revision.
- A day later, Morgan Stanley’s Jeffrey Hung (a top 16% rated analyst) upgraded Jazz stock from a Hold rating to a Strong Buy, and increased his price target from $175 to $183.
- In a note shared with investors, Hung attributed an increase in revenue estimates for several of the company’s products as the catalyst that caused the upgrade.
- Jazz Pharmaceuticals has an overall Zen Rating of A — in fact, once all of the 115 factors tracked by our proprietary quant rating system are taken into account, JAZZ stock ranks in the top 2% of equities.
- While it performs admirably in terms of Growth, Safety, and Financials, JAZZ stock stands out primarily through its Value Component Grade rating of A — in this category, the stock ranks in the top 1%. (See all 7 Zen Component Grades here >)
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.